Diffusion Pharmaceuticals, Inc. (DFFN)
| Market Cap | 69.14M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -15.83M |
| Shares Out | 64.01M |
| EPS (ttm) | -0.38 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 20 |
| Last Price | $1.07 |
| Previous Close | $1.04 |
| Change ($) | 0.03 |
| Change (%) | 2.88% |
| Day's Open | 1.04 |
| Day's Range | 1.04 - 1.25 |
| Day's Volume | 4,682,564 |
| 52-Week Range | 0.26 - 1.50 |
CHARLOTTESVILLE, Va., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), today announced that the Company is participating in the H...
Diffusion Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business Updates
Initiated and Advanced C linical Trial Evaluating Lead Product Candidate in COVID-19 Patients
CHARLOTTESVILLE, Va., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), today announced the appointment of Christopher D. Galloway...
CHARLOTTESVILLE, Va., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (N asdaq : DFFN) (“Diffusion” or “the Company”) today announced the appointment of William Elder, J.D....
CHARLOTTESVILLE, Va., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), today announced its management will present at the H.C....
Diffusion Pharmaceuticals Names Director Dr. Robert Cobuzzi as President and Chief Executive Officer
CHARLOTTESVILLE, Va., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), today announced that Robert (“Bob”) J. Cobuzzi Jr., Ph....
Romanian Regulatory Approval Received to Begin Phase 1b COVID-19 Clinical Trial Romanian Regulatory Approval Received to Begin Phase 1b COVID-19 Clinical Trial
Diffusion Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Business Update
Continues global clinical development of TSC for the treatment of COVID-19 Continues global clinical development of TSC for the treatment of COVID-19
Diffusion Pharmaceuticals (NASDAQ: DFFN) shares are trading lower on Monday after the company received guidance from the FDA on the company's IND for trans sodium crocetinate in Covid-19 patie...
Guidance being incorporated into global study protocol Enrollment of first patient now expected in August
Diffusion Pharmaceuticals Files IND for International Phase 1b/2b COVID-19 Clinical Program With TSC
Phase 1b dosing expected to begin this month Data read-out expected later this quarter
Dosing expected to begin in Q2 2020 with first data in Q3 2020 Trial expected to enroll 224 patients over 12 months, with 24 patients immediately U.S. IND filing planned for later this month D...
Share price exceeds $1 at closing for 10 consecutive trading days Share price exceeds $1 at closing for 10 consecutive trading days
Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) shares pushed higher to start the week after the company announced a critical update from the U.S.
CHARLOTTESVILLE, Va., May 20, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), a cutting-edge biotechnology company developing new treat...
Inclusion in FDA’s Coronavirus Treatment Acceleration Program significantly shortens regulatory review cycles
Diffusion Pharmaceuticals Inc (NASDAQ: DFFN) shares were more than doubling Wednesday following an announcement by the company regarding testing of its lead asset for COVID-19-related complica...
Partnering with University of Virginia Health and iTHRIV Partnering with University of Virginia Health and iTHRIV
Overtaxed healthcare systems will delay enrollment in some geographic locations Overtaxed healthcare systems will delay enrollment in some geographic locations
Dr. Gainer to remain on board of directors Dr. Gainer to remain on board of directors
CHARLOTTESVILLE, Va., Feb. 07, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or “the Company”), a cutting-edge biotechnology company developing new trea...
CHARLOTTESVILLE, Va., Jan. 10, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion,” the “Company,” “we,” “our” or “us”), a cutting-edge biotechnology company ...
CHARLOTTESVILLE, Va., Dec. 13, 2019 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion,” the “Company,” “we,” “our” or “us”) today announced the closing of its pre...
CHARLOTTESVILLE, Va., Dec. 12, 2019 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN), please note that the prici...
Presentation Made by Chief Scientific Officer John Gainer at the Inaugural Glioblastoma Drug Development Summit Presentation Made by Chief Scientific Officer John Gainer at the Inaugural Gliob...
Diffusion Pharmaceuticals is a tiny micro-cap with market cap between $4.6m and $11.1m (based on a price of $0.285), developing an add-on treatment for brain cancer (glioblastoma) and stroke.
Chief Scientific Officer Dr. John Gainer to Present at Inaugural Glioblastoma Drug Development Summit Chief Scientific Officer Dr. John Gainer to Present at Inaugural Glioblastoma Drug Develop...
CHARLOTTESVILLE, Va., Nov. 15, 2019 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion,” the “Company,” “we,” “our” or “us”) a clinical-stage biotechnology company...
CHARLOTTESVILLE, Va., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or the “Company”), a clinical-stage biotechnology company developing new tr...
CHARLOTTESVILLE, Va., Oct. 17, 2019 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening med...
Diffusion Pharmaceuticals to Present at the H.C. Wainwright 21st Annual Global Investment Conference
CHARLOTTESVILLE, Va., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening me...
Year to date, the market has gifted investors a 9.92% return, but it remains off 5.73% from the start of the fourth quarter. While many investors are enjoying a lift in their stocks, the Ben G...
About DFFN
Diffusion Pharmaceuticals, a clinical stage biotechnology company, develops treatments for life-threatening medical conditions. Its lead product candidate is transcrocetinate sodium, which is in Phase III trials for the treatment of glioblastoma multiforme (GBM); Phase II clinical trials for the treatment of metastatic brain cancer; and Phase II trial for the treatment of acute stroke. The company is also developing RES-529, a PI3K/Akt/mTOR pathway inhibitor, which has completed two Phase I clinical trials for the treatment of age-related macul... [Read more...]
| Industry Biotechnology | Founded 2001 |
| Stock Exchange NASDAQ | Ticker Symbol DFFN |
Analyst Forecasts
According to one analyst, the rating for DFFN stock is "Hold" and the 12-month stock price forecast is 2.75.